Trialo

Trialo is transforming drug development through AI-powered clinical evidence intelligence. Our platform automatically extracts and analyzes efficacy endpoints from regulatory submissions, scientific literature, company announcements, and public documents—enabling pharmaceutical companies, investors, and research organizations to make faster, more confident development decisions. Our comprehensive suite of tools includes: • DiseaseXplorer™ for indication-centric analytics • Smart Endpoint Analytics for standardized efficacy comparisons • AI Research Assistant for instant, evidence-based insights • Source Document Verification for regulatory-grade validation Through our advanced AI architecture and proprietary trial endpoint recognition technology, we process tens of thousands of clinical documents to deliver structured, actionable insights. Our platform helps clients compare drug efficacy across therapeutic areas, optimize trial designs, identify market opportunities, and generate regulatory-grade evidence summaries in minutes rather than months. Founded by veterans in drug development and AI engineering, we're committed to accelerating innovation in life sciences by making clinical evidence more accessible and actionable than ever before. Specialties: Clinical Trial Analytics, Drug Development Intelligence, AI-Powered Research, Regulatory Intelligence, Clinical Evidence Analysis, Trial Design Optimization, Drug Efficacy Comparison, Market Assessment, Healthcare Technology.